MAY 21, 2020 6:49 AM PDT

A New Player in the Regulation of Cancer's Microenvironment

WRITTEN BY: Jasper Cantrell

Breast cancer is one of the most common cancers in the world. Triple-negative breast cancer (TNBC) is a sub-type of breast cancer characterized by its appearance in younger women and its relative aggressiveness. TNBC is resistant to hormonal, chemo, and targeted therapies. A team from Taiwan conducted a cDNA array to identify any genes that were at abnormal levels in TNBC and found the multiple epidermal growth factor-like domain 11 (MEGF11) gene to be upregulated.

The MEGF family of proteins has been a target of research in recent years. MEGF10 was identified in previous work as a glioblastoma suppressor, and MEGF8 has been linked to Carpenter Syndrome. MEGF11 is still very new, with little research done to determine its role in the cell.

The group began by running some in vitro assays using two TNBC cell lines. They knocked out MEGF11 in both cell lines and measured the effect versus wild-type controls. The MEGF11 knockouts had significantly decreased growth compared to controls. They also noticed the inactivation of Akt, mTOR, and NF-kB pathways, which considering their importance in cellular proliferation, could account for the increased doubling time. They also noticed a decrease in the levels of several chemokines and pro-inflammatory cytokines.

Conversely, overexpressing MEGF11 increased the levels of the same chemokines and cytokines. Interestingly, it did not actually change the growth of the TNBC cell lines. Investigating into this, they found that only the Akt pathway had a significant increase in activation upon MEGF11 overexpression. The Akt pathway was proposed to be the cause of the increase in cytokine and chemokine production. One chemokine, IL-17a, was found to have a direct effect on MEGF11 levels. When MEGF11 was overexpressed, IL-17a also increased in levels. When IL-17a was added to a TNBC cell line culture, MEGF11 levels were found to increase.

IL-17a addition saw an increase in a few other chemokines and cytokines as well. A mouse experiment showed that a MEGF11 knockout TNBC tumor in mice showed decreased tumor size compared to controls. They also noted lower levels of TNBC cells in the blood, inferring a possible decrease in metastasis.
Altogether, the group proposes that MEGF11 has a role in the regulation of cytokine and chemokine production in TNBC. Many tumors often change the microenvironment surrounding them, which can prevent an immune response, stimulate growth, or even increase the likelihood of metastasis. MEGF11’s connection to IL-17a makes it a likely candidate for regulating the tumors microenvironment, as IL-17a is known to accumulate around tumors and influence the immune system. The team concludes, “Our results demonstrate that MEGF11 play important role in tumour survival and that overexpression of MEGF11 induces both cytokine and chemokine cascades, which in turn will bring about modulation of the tumour microenvironments within TNBC cells.”

Sources: Nature, Albert Einstein College of Medicine
 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUL 16, 2021
Cancer
Exercise Slows Growth of Bowel Cancer Cells
JUL 16, 2021
Exercise Slows Growth of Bowel Cancer Cells
Exercise releases molecules into the bloodstream that reduce the growth of bowel cancer cells, say researchers from the ...
JUL 16, 2021
Drug Discovery & Development
Machine Learning Ranks Cancer Drugs by Efficacy
JUL 16, 2021
Machine Learning Ranks Cancer Drugs by Efficacy
A machine learning algorithm developed by researchers at the Queen Mary University of London in the UK can rank cancer d ...
AUG 04, 2021
Health & Medicine
Cannabis Drug Sativex to Be Tested in Phase II Brain Tumor Trial
AUG 04, 2021
Cannabis Drug Sativex to Be Tested in Phase II Brain Tumor Trial
  A phase II trial is being planned to test the cannabis-derived drug Sativex, in patients with aggressive brain tu ...
SEP 23, 2021
Immunology
Enhanced Hamster Cells as Super Drug Factories
SEP 23, 2021
Enhanced Hamster Cells as Super Drug Factories
Antibodies are highly specialized proteins produced by the immune system that stick on to foreign invaders in the body w ...
OCT 14, 2021
Cancer
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
OCT 14, 2021
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
Colorectal cancer develops when a series of changes occur across multiple genes.  While researchers have paid signi ...
OCT 28, 2021
Cancer
NF-κB: a Trick or a Treat for Cancer?
OCT 28, 2021
NF-κB: a Trick or a Treat for Cancer?
A family of proteins, known as transcription factors, regulate the biological process of converting DNA into RNA. T ...
Loading Comments...